Sanofi Shares Outstanding 2012-2026 | SNY

Sanofi shares outstanding history from 2012 to 2026. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Sanofi shares outstanding for the quarter ending June 30, 2026 were 2.393B, a 1.68% decline year-over-year.
  • Sanofi 2025 shares outstanding were 2.451B, a 2.43% decline from 2024.
  • Sanofi 2024 shares outstanding were 2.512B, a 0.02% decline from 2023.
  • Sanofi 2023 shares outstanding were 2.513B, a 0.04% decline from 2022.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Sanofi Annual Shares Outstanding
(Millions of Shares)
2025 2,451
2024 2,512
2023 2,513
2022 2,514
2021 2,516
2020 2,520
2019 2,514
2018 2,510
2017 2,534
2016 2,592
2015 2,641
2014 2,662
2013 2,675
2012 2,656
2011 2,643
Sanofi Quarterly Shares Outstanding
(Millions of Shares)
2026-06-30 2,393
2026-03-31 2,408
2025-12-31 2,451
2025-09-30 2,436
2025-06-30 2,434
2025-03-31 2,468
2024-12-31 2,512
2024-09-30 2,506
2024-06-30 2,500
2024-03-31 2,498
2023-12-31 2,513
2023-09-30 2,506
2023-06-30 2,501
2023-03-31 2,499
2022-12-31 2,514
2022-09-30 2,507
2022-06-30 2,502
2022-03-31 2,498
2021-09-30 2,509
2021-03-31 2,499
2020-09-30 2,511
2020-03-31 2,503
2019-09-30 2,504
2019-03-31 2,498
2018-03-31 2,496
2017-12-31 2,534
2017-09-30 2,509
2017-06-30 2,516
2017-03-31 2,525
2016-12-31 2,592
2016-09-30 2,577
2016-06-30 2,574
2016-03-31 2,577
2015-09-30 2,611
2015-06-30 2,612
2014-06-30 2,634
2013-06-30 2,691
2012-06-30 2,631
2012-03-31 2,642
2011-12-31 2,660
2011-09-30 2,678
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $102.796B $49.347B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $1069.485B 36.08
Johnson & Johnson (JNJ) United States $643.925B 24.60
AbbVie (ABBV) United States $464.737B 24.20
Merck (MRK) United States $354.755B 44.79
Roche Holding AG (RHHBY) Switzerland $350.029B 0.00
Novartis AG (NVS) Switzerland $264.508B 15.97
Novo Nordisk (NVO) Denmark $189.896B 10.58
Pfizer (PFE) United States $157.026B 9.03
Bayer (BAYRY) Germany $55.158B 9.81
Innoviva (INVA) United States $1.506B 5.15